Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by TechOneon Jul 20, 2022 8:51pm
307 Views
Post# 34838953

RE:RE:RE:RE:Don't sell your shares!

RE:RE:RE:RE:Don't sell your shares!Long term share holders all know the prospects in terms of PMX, history, in terms of previous results as well as new TIGRIS trial with enough leeway to allow them to do a proper job of it, all the numbers from Japan and Italy and previous study there and now with selected patients being enrolled at a steady clip, it is as good as it is going to get..  Today's news release was totally unexpected since the management had made it clear that they were not going to jeopardize the trial and run afoul with FDA by issuing any premature results..

And let's not forget that Spectral is not a one trick poney.. Dialco with already approved SAMI and pretty soon the DIMI we have a subsidiary that is worth any where from half a billion to as much as 2 billion if previous deals are any guide.. We already have one deal and with the new guy, whose claim to fame is his rolodex with access to all manners of right people, we are going to be surprised one of these days with some other deals.. Hopefully..

So who in their right mind would sell the shares where the marketcap is a lousy 150+ million..

No doubt, The game is afoot.. Every news release that comes out of the company will be looked over closely and parsed for sure.. Breakthrough Device designation and if we have interim results at some point that blows out the numbers, anything is possible..

FWIW

p.s. And yes, a .01 move in shares is worth a lot of money, up or down, for some of the players here so let's not even go there.. :)

<< Previous
Bullboard Posts
Next >>